Cargando…
Dysregulation of mTOR activity through LKB1 inactivation
Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either du...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sun Yat-sen University Cancer Center
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845579/ https://www.ncbi.nlm.nih.gov/pubmed/23668926 http://dx.doi.org/10.5732/cjc.013.10086 |